Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma
Journal of Ovarian Research Aug 11, 2017
Jiang RT, et al. – Here, researchers sought to find out whether RPN13 is available as a target in precursors of ovarian/fallopian tube cancer and also all advanced cases and the effect of increased ADRM1 gene copy number on the sensitivity of ovarian cancer to RA190. RPN13 can potentially be targeted by RA190 in both in situ and metastatic ovarian carcinoma. Ovarian cancer cell lines are sensitive to RA190 regardless of whether the ADRM1 gene is amplified.
Methods
- ADRM1 mRNA was measured by RNAscope in situ hybridization and RPN13 protein detected by immunohistochemistry in high–grade serous carcinoma (HGSC) of the ovary and serous tubal intraepithelial carcinoma (STIC).
- Amplification of ADRM1 and sensitivity to RA190 were determined in ovarian cancer cell lines.
Results
- Here, they show that expression of ADRM1mRNA is significantly elevated in STIC and HGSC as compared to normal fallopian tube epithelium.
- ADRM1 mRNA and RPN13 were ubiquitously and robustly expressed in ovarian carcinoma tissue and cell lines.
- No correlation was observed between ADRM1 amplification and sensitivity of ovarian cancer cell lines to RA190, but all were susceptible.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries